AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
BioPharmaceuticals: R&I: Symbicor... |
-- | 2,362 | 2,538 | 2,728 | 2,721 | 2,495 |
BioPharmaceuticals: R&I: Pulmicor... |
-- | 713 | 645 | 962 | 996 | 1,466 |
BioPharmaceuticals: R&I: Fasenra:... |
-- | 1,553 | 1,396 | 1,258 | 949 | 704 |
BioPharmaceuticals: CVRM: Brilint... |
-- | 1,324 | 1,358 | 1,472 | 1,593 | 1,581 |
BioPharmaceuticals: CVRM: Farxiga... |
-- | 5,963 | 4,381 | 3,000 | 1,959 | 1,543 |
BioPharmaceuticals: R&I: Breztri:... |
-- | 677 | 398 | 203 | 28 | 2 |
BioPharmaceuticals: CVRM: Lokelma... |
-- | 412 | 289 | 175 | 76 | 14 |
Rare Disease: Koselugo: World [$M... |
-- | 331 | 208 | 108 | 38 | -- |
Oncology: World [$M] |
-- | 17,145 | 14,631 | 13,048 | 10,850 | 8,667 |
BioPharmaceuticals: CVRM: World [... |
-- | 10,585 | 9,188 | 8,020 | 7,096 | -- |
BioPharmaceuticals: R&I: World [$... |
-- | 6,107 | 5,765 | 6,034 | 5,357 | -- |
BioPharmaceuticals: CVRM: roxadus... |
-- | -- | 0 | 174 | 30 | -- |
BioPharmaceuticals: V&I: FluMist:... |
-- | 216 | 175 | 253 | -- | -- |
Oncology: Others: World [$M] |
-- | 224 | 44 | 50 | -- | -- |
BioPharmaceuticals: CVRM: Others:... |
-- | 296 | 366 | 196 | -- | -- |
BioPharmaceuticals: R&I: Others: ... |
-- | 324 | 421 | 594 | -- | -- |
Oncology: Enhertu: World [$M] |
-- | 261 | 79 | 17 | -- | -- |
Oncology: Tagrisso: Emerging Mark... |
-- | 1,621 | 1,567 | -- | -- | -- |
Oncology: Imfinzi: Emerging Marke... |
-- | 360 | 287 | -- | -- | -- |
Oncology: Lynparza: Emerging Mark... |
-- | 542 | 488 | -- | -- | -- |
Oncology: Calquence: Emerging Mar... |
-- | 98 | 45 | -- | -- | -- |
Oncology: Enhertu: Emerging Marke... |
-- | 169 | 51 | -- | -- | -- |
Oncology: Orpathys: Emerging Mark... |
-- | 44 | 33 | -- | -- | -- |
Oncology: Zoladex: Emerging Marke... |
-- | 687 | 657 | -- | -- | -- |
Oncology: Others: Emerging Market... |
-- | 165 | 27 | -- | -- | -- |
Oncology: Emerging Markets Total ... |
-- | 3,828 | 3,537 | -- | -- | -- |
BioPharmaceuticals: CVRM: Farxiga... |
-- | 2,211 | 1,665 | -- | -- | -- |
BioPharmaceuticals: CVRM: Brilint... |
-- | 285 | 286 | -- | -- | -- |
BioPharmaceuticals: CVRM: Lokelma... |
-- | 50 | 20 | -- | -- | -- |
BioPharmaceuticals: CVRM: roxadus... |
-- | 271 | 197 | -- | -- | -- |
BioPharmaceuticals: CVRM: Crestor... |
-- | 862 | 794 | -- | -- | -- |
BioPharmaceuticals: CVRM: Seloken... |
-- | 621 | 839 | -- | -- | -- |
BioPharmaceuticals: CVRM: Others:... |
-- | 152 | 194 | -- | -- | -- |
BioPharmaceuticals: CVRM: Emergin... |
-- | 4,586 | 4,119 | -- | -- | -- |
BioPharmaceuticals: R&I: Symbicor... |
-- | 753 | 608 | -- | -- | -- |
BioPharmaceuticals: R&I: Fasenra:... |
-- | 64 | 43 | -- | -- | -- |
BioPharmaceuticals: R&I: Breztri:... |
-- | 161 | 92 | -- | -- | -- |
BioPharmaceuticals: R&I: Pulmicor... |
-- | 575 | 462 | -- | -- | -- |
BioPharmaceuticals: R&I: Others: ... |
-- | 206 | 230 | -- | -- | -- |
BioPharmaceuticals: R&I: Emerging... |
-- | 1,771 | 1,443 | -- | -- | -- |
BioPharmaceuticals: V&I: Synagis:... |
-- | 195 | 173 | -- | -- | -- |
BioPharmaceuticals: V&I: Emerging... |
-- | 212 | 1,316 | -- | -- | -- |
Rare Disease: Soliris: Emerging M... |
-- | 424 | 301 | -- | -- | -- |
Rare Disease: Ultomiris: Emerging... |
-- | 71 | 38 | -- | -- | -- |
Rare Disease: Strensiq: Emerging ... |
-- | 40 | 35 | -- | -- | -- |
Rare Disease: Koselugo: Emerging ... |
-- | 59 | 26 | -- | -- | -- |
Rare Disease: Kanuma: Emerging Ma... |
-- | 29 | 31 | -- | -- | -- |
Rare Disease: Emerging Markets [$... |
-- | 623 | 431 | -- | -- | -- |
Other Medicines: Nexium: Emerging... |
-- | 578 | 568 | -- | -- | -- |
Other Medicines: Others: Emerging... |
-- | 153 | 220 | -- | -- | -- |
Other Medicines: Emerging Markets... |
-- | 731 | 788 | -- | -- | -- |
Oncology: Tagrisso: Established R... |
-- | 782 | 847 | -- | -- | -- |
Oncology: Imfinzi: Established Ro... |
-- | 802 | 401 | -- | -- | -- |
Oncology: Lynparza: Established R... |
-- | 281 | 269 | -- | -- | -- |
Oncology: Calquence: Established ... |
-- | 108 | 69 | -- | -- | -- |
Oncology: Zoladex: Established Ro... |
-- | 118 | 122 | -- | -- | -- |
Oncology: Others: Established RoW... |
-- | 47 | 10 | -- | -- | -- |
Oncology: Established RoW [$M] |
-- | 2,266 | 1,884 | -- | -- | -- |
BioPharmaceuticals: CVRM: Andexxa... |
-- | 45 | 32 | -- | -- | -- |
BioPharmaceuticals: CVRM: Establi... |
-- | 744 | 684 | -- | -- | -- |
BioPharmaceuticals: R&I: Symbicor... |
-- | 334 | 375 | -- | -- | -- |
BioPharmaceuticals: R&I: Fasenra:... |
-- | 142 | 142 | -- | -- | -- |
BioPharmaceuticals: R&I: Breztri:... |
-- | 52 | 34 | -- | -- | -- |
BioPharmaceuticals: R&I: Saphnelo... |
-- | 10 | 3 | -- | -- | -- |
BioPharmaceuticals: R&I: Pulmicor... |
-- | 42 | 49 | -- | -- | -- |
BioPharmaceuticals: R&I: Others: ... |
-- | 6 | 6 | -- | -- | -- |
BioPharmaceuticals: R&I: Establis... |
-- | 625 | 613 | -- | -- | -- |
Oncology: Orpathys: World [$M] |
-- | 44 | 33 | -- | -- | -- |
BioPharmaceuticals: CVRM: Andexxa... |
-- | 182 | 150 | -- | -- | -- |
BioPharmaceuticals: R&I: Saphnelo... |
-- | 280 | 116 | -- | -- | -- |
BioPharmaceuticals: V&I: World [$... |
-- | 1,012 | 4,736 | -- | -- | -- |
BioPharmaceuticals: V&I: Establis... |
-- | 295 | 1,225 | -- | -- | -- |
BioPharmaceuticals: V&I: Synagis:... |
-- | 177 | 191 | -- | -- | -- |
Rare Disease: Soliris: World [$M] |
-- | 3,145 | 3,762 | -- | -- | -- |
Rare Disease: Soliris: Establishe... |
-- | 317 | 476 | -- | -- | -- |
Rare Disease: Ultomiris: Establis... |
-- | 476 | 310 | -- | -- | -- |
Rare Disease: Ultomiris: World [$... |
-- | 2,965 | 1,965 | -- | -- | -- |
Product Sales: Rare Disease: Stre... |
-- | 1,152 | 958 | -- | -- | -- |
Rare Disease: Strensiq: Establish... |
-- | 86 | 76 | -- | -- | -- |
Rare Disease: Koselugo: Establish... |
-- | 24 | 0 | -- | -- | -- |
Rare Disease: Kanuma: Established... |
-- | 8 | 8 | -- | -- | -- |
Rare Disease: Kanuma: World [$M] |
-- | 171 | 160 | -- | -- | -- |
Product Sales: Rare Disease: Worl... |
-- | 7,764 | 7,053 | -- | -- | -- |
Rare Disease: Established RoW [$M... |
-- | 911 | 870 | -- | -- | -- |
Other Medicines: Nexium: Establis... |
-- | 199 | 551 | -- | -- | -- |
Other Medicines: Others: Establis... |
-- | 8 | 19 | -- | -- | -- |
Other Medicines: Others: World [$... |
-- | 231 | 340 | -- | -- | -- |
Other Medicines: Established RoW ... |
-- | 207 | 570 | -- | -- | -- |
Other Medicines: World [$M] |
-- | 1,176 | 1,625 | -- | -- | -- |
Total Product Sales: Emerging Mar... |
-- | 11,751 | 11,634 | -- | -- | -- |
Collaboration Revenue: Total [$M] |
-- | 594 | 1,353 | -- | -- | -- |
BioPharmaceuticals: R&I: Saphnelo... |
-- | 2 | -- | -- | -- | -- |
Oncology: Tagrisso: World [$M] |
-- | 5,799 | 5,444 | 5,015 | 4,328 | 3,189 |
Oncology: Imfinzi: World [$M] |
-- | 4,237 | 2,784 | 2,412 | 2,042 | 1,469 |
Oncology: Lynparza: World [$M] |
-- | 2,811 | 2,638 | 2,348 | 1,776 | 1,198 |
Oncology: Calquence: World [$M] |
-- | 2,514 | 2,057 | 1,238 | 522 | 164 |
Oncology: Zoladex: World [$M] |
-- | 952 | 927 | 948 | 888 | 813 |
BioPharmaceuticals: V&I: Synagis:... |
-- | 546 | 578 | 410 | 372 | 358 |
Other medicines: Nexium: World [$... |
-- | 945 | 1,285 | 1,326 | 1,492 | 1,483 |
BioPharmaceuticals: CVRM: Crestor... |
-- | 1,107 | 1,048 | 1,096 | 1,180 | 1,278 |
BioPharmaceuticals: CVRM: Seloken... |
-- | 640 | 862 | 951 | 821 | 760 |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
BioPharmaceuticals: R&I: Symbicor... |
-- | 726 | 973 | 1,065 | 1,022 | 829 |
BioPharmaceuticals: R&I: Pulmicor... |
-- | 28 | 65 | 72 | 71 | 110 |
BioPharmaceuticals: CVRM: Crestor... |
-- | 55 | 65 | 80 | 92 | 104 |
BioPharmaceuticals: CVRM: Seloken... |
-- | 1 | 0 | 1 | 13 | 37 |
Oncology: Zoladex: U.S. [$M] |
-- | 14 | 15 | 13 | 5 | 7 |
Oncology: Tagrisso: U.S. [$M] |
-- | 2,276 | 2,007 | 1,780 | 1,566 | 1,268 |
Other Medicines: Nexium: U.S. [$M... |
-- | 115 | 120 | 128 | 169 | 218 |
BioPharmaceuticals: R&I: Fasenra:... |
-- | 992 | 906 | 790 | 603 | 482 |
BioPharmaceuticals: CVRM: Brilint... |
-- | 744 | 744 | 735 | 732 | 710 |
Oncology: Lynparza: U.S. [$M] |
-- | 1,254 | 1,226 | 1,087 | 876 | 626 |
Oncology: Imfinzi: U.S. [$M] |
-- | 2,317 | 1,552 | 1,245 | 1,185 | 1,041 |
Oncology: Calquence: U.S. [$M] |
-- | 1,815 | 1,657 | 1,089 | 511 | 162 |
BioPharmaceuticals: CVRM: Farxiga... |
-- | 1,451 | 1,071 | 732 | 569 | 537 |
BioPharmaceuticals: CVRM: Lokelma... |
-- | 214 | 170 | 115 | 57 | 13 |
Rare Disease: Koselugo: U.S. [$M] |
-- | 195 | 162 | 104 | 38 | -- |
Oncology: U.S. [$M] |
-- | 7,719 | 6,484 | 5,359 | 4,250 | 3,449 |
BioPharmaceuticals: CVRM: U.S. [$... |
-- | 2,752 | 2,479 | 2,124 | 2,083 | -- |
BioPharmaceuticals: R&I: U.S. [$M... |
-- | 2,547 | 2,655 | 2,404 | 1,941 | -- |
Total Product Sales: Total World ... |
-- | 43,789 | 42,998 | 36,541 | 25,890 | 23,565 |
Total Product Sales: U.S. Sales [... |
-- | 17,961 | 17,254 | 12,000 | 8,638 | 7,747 |
BioPharmaceuticals: V&I: FluMist:... |
-- | 23 | 21 | 27 | -- | -- |
BioPharmaceuticals: R&I: Saphnelo... |
-- | 260 | 111 | -- | -- | -- |
Oncology: Europe [$M] |
-- | 3,332 | 2,726 | -- | -- | -- |
BioPharmaceuticals: CVRM: Farxiga... |
-- | 1,881 | 1,297 | -- | -- | -- |
BioPharmaceuticals: CVRM: Brilint... |
-- | 271 | 282 | -- | -- | -- |
BioPharmaceuticals: CVRM: Lokelma... |
-- | 58 | 30 | -- | -- | -- |
BioPharmaceuticals: CVRM: Andexxa... |
-- | 62 | 41 | -- | -- | -- |
BioPharmaceuticals: CVRM: Crestor... |
-- | 52 | 41 | -- | -- | -- |
BioPharmaceuticals: CVRM: Seloken... |
-- | 11 | 14 | -- | -- | -- |
BioPharmaceuticals: CVRM: Others:... |
-- | 109 | 128 | -- | -- | -- |
BioPharmaceuticals: CVRM: Europe ... |
-- | 2,503 | 1,906 | -- | -- | -- |
BioPharmaceuticals: R&I: Symbicor... |
-- | 549 | 582 | -- | -- | -- |
BioPharmaceuticals: R&I: Fasenra:... |
-- | 355 | 305 | -- | -- | -- |
BioPharmaceuticals: R&I: Breztri:... |
-- | 81 | 33 | -- | -- | -- |
BioPharmaceuticals: R&I: Pulmicor... |
-- | 68 | 69 | -- | -- | -- |
BioPharmaceuticals: R&I: Others: ... |
-- | 30 | 42 | -- | -- | -- |
BioPharmaceuticals: R&I: Saphnelo... |
-- | 8 | 2 | -- | -- | -- |
BioPharmaceuticals: R&I: Europe [... |
-- | 1,164 | 1,054 | -- | -- | -- |
BioPharmaceuticals: V&I: Europe [... |
-- | 396 | 1,027 | -- | -- | -- |
BioPharmaceuticals: V&I: Synagis:... |
-- | 175 | 213 | -- | -- | -- |
BioPharmaceuticals: V&I: FluMist:... |
-- | 188 | 151 | -- | -- | -- |
Rare Disease: Soliris: Europe [$M... |
-- | 670 | 805 | -- | -- | -- |
Other Medicines: Nexium: Europe [... |
-- | 53 | 46 | -- | -- | -- |
Other Medicines: Others: Europe [... |
-- | 52 | 77 | -- | -- | -- |
Rare Disease: Europe [$M] |
-- | 1,529 | 1,428 | -- | -- | -- |
Other Medicines: Europe [$M] |
-- | 105 | 123 | -- | -- | -- |
BioPharmaceuticals: CVRM: Farxiga... |
-- | 420 | 348 | -- | -- | -- |
BioPharmaceuticals: CVRM: Brilint... |
-- | 24 | 46 | -- | -- | -- |
BioPharmaceuticals: CVRM: Lokelma... |
-- | 90 | 69 | -- | -- | -- |
BioPharmaceuticals: CVRM: Crestor... |
-- | 138 | 148 | -- | -- | -- |
BioPharmaceuticals: CVRM: Seloken... |
-- | 7 | 9 | -- | -- | -- |
BioPharmaceuticals: CVRM: Others:... |
-- | 5 | 10 | -- | -- | -- |
BioPharmaceuticals: CVRM: Andexxa... |
-- | 75 | 77 | -- | -- | -- |
BioPharmaceuticals: CVRM: Others:... |
-- | 30 | 34 | -- | -- | -- |
BioPharmaceuticals: R&I: Other: U... |
-- | 82 | 143 | -- | -- | -- |
BioPharmaceuticals: R&I: Breztri:... |
-- | 383 | 239 | -- | -- | -- |
Rare Disease: Soliris: U.S. [$M] |
-- | 1,734 | 2,180 | -- | -- | -- |
Rare Disease: Ultomiris: U.S. [$M... |
-- | 1,750 | 1,136 | -- | -- | -- |
Rare Disease: Strensiq: U.S. [$M] |
-- | 937 | 769 | -- | -- | -- |
Rare Disease: Kanuma: U.S. [$M] |
-- | 85 | 77 | -- | -- | -- |
Rare Disease: U.S. [$M] |
-- | 4,701 | 4,324 | -- | -- | -- |
Other Medicines: Others: U.S. [$M... |
-- | 18 | 24 | -- | -- | -- |
Other Medicines: U.S. [$M] |
-- | 133 | 144 | -- | -- | -- |
Rare Disease: Ultomiris: Europe [... |
-- | 668 | 481 | -- | -- | -- |
Rare Disease: Strensiq: Europe [$... |
-- | 89 | 78 | -- | -- | -- |
Rare Disease: Koselugo: Europe [$... |
-- | 53 | 20 | -- | -- | -- |
Rare Disease: Kanuma: Europe [$M] |
-- | 49 | 44 | -- | -- | -- |
Total Product Sales: Europe [$M] |
-- | 9,029 | 8,264 | -- | -- | -- |
Total Product Sales: Established ... |
-- | 5,048 | 5,846 | -- | -- | -- |
BioPharmaceuticals: V&I: FluMist:... |
-- | 4 | 2 | -- | -- | -- |
BioPharmaceuticals: V&I: U.S. [$M... |
-- | 109 | 1,168 | -- | -- | -- |
Oncology: Tagrisso: Europe [$M] |
-- | 1,120 | 1,023 | -- | -- | -- |
Oncology: Imfinzi: Europe [$M] |
-- | 758 | 544 | -- | -- | -- |
Oncology: Lynparza: Europe [$M] |
-- | 734 | 655 | -- | -- | -- |
Oncology: Calquence: Europe [$M] |
-- | 493 | 286 | -- | -- | -- |
Oncology: Enhertu: Europe [$M] |
-- | 60 | 21 | -- | -- | -- |
Oncology: Enhertu: Established Ro... |
-- | 32 | 7 | -- | -- | -- |
Oncology: Zoladex: Europe [$M] |
-- | 133 | 133 | -- | -- | -- |
Oncology: Others: Europe [$M] |
-- | 6 | 6 | -- | -- | -- |